Nisha Devi

Template:CharacterInfobox Dr. Nisha Devi is a senior researcher of the Interstellar Health Organisation. In August 3307, she issued a report indicating that Onionhead Gamma Strain appeared to have genuine medicinal properties based on observations of the drug's users, a conclusion that supported claims made by the Kumo Crew and the results of clinical trials undertaken by Neomedical Industries.

Timeline

The pharmaceutical giant Neomedical Industries aims to mass-produce onionhead gamma strain as a medicine. The announcement follows a report from the Interstellar Health Organisation, which details how the new onionhead variant is an effective treatment for many psychological and musculoskeletal conditions. Olwyn Kendrick, CEO of Neomedical Industries, told the media: "The IHO has confirmed the findings of our research of onionhead gamma strain's use for specific medical purposes. Clinical trials prove that its psychedelic qualities are no more intense than the side effects of conventional neuroleptics. It is inappropriate that a crime syndicate should provide a product that can relieve the suffering of millions. Therefore, we aim to build our own stockpile to expedite its distribution to common markets." This statement was viewed as controversial in some quarters, particularly within the Federation. However, there have been expressions of interest from many independent factions. The Kumo Crew syndicate, which manufactures and distributes onionhead gamma strain, has offered no response as yet. Neomedical Industries is one of the two largest pharmaceutical companies in the galaxy, alongside Vandermeer Corporation. It provides healthcare services and equipment exclusively to Alliance and independent systems.^[1]

24 AUG 3307

The Interstellar Health Organisation has validated the Kumo Crew's claim that onionhead gamma strain, also known as 'helix', has medicinal properties. Dr Nisha Devi, one of the IHO's senior researchers, told the media: "We have analysed user data in the independent systems where onionhead gamma strain is on sale. Unexpectedly, the initial marketing claims that 'helix' can be used for medicinal purposes have been authenticated. A significant percentage of customers are believed to be using the drug for healthcare reasons rather than recreational use. Reports show that it is a successful treatment for many psychological disorders, bringing faster results than conventional neuroleptics. It may also provide effective symptomatic relief for patients with musculoskeletal conditions. Several research facilities are now running clinical trials on the viability of using onionhead gamma strain in medical practice. The IHO is monitoring these studies and will publish the results." Vandermeer Corporation, the largest pharmaceutical company in the Federation, published a statement from its head of marketing Ronan Roscoe: "These conclusions are biased and informed by inaccurate data. We maintain that all forms of onionhead are dangerous narcotics with long-term detriments to health. Vandermeer's antipsychotic treatments are effective without the side effects of mild psychedelic experiences."^[2]